TrialPath
Recruiting

Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease

NCT06203249 · Chinese PLA General Hospital
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Microecology and Host Immunity in Patients With Anti-melanoma Differentiation Associated Gene 5 Antibody Positive Dermatomyositis and Interstitial Lung Disease
About this study
Methods: Bronchoalveolar lavage specimens of patients with anti-MDA5 antibody positive dermatomyositis and interstitial lung disease were collected and studied to analyze the relationship between the composition of patients' microecology and the occurrence and development of disease.
Eligibility criteria
Inclusion Criteria: * Patients who meet the diagnostic criteria of dermatomyositis and anti-MDA 5 antibody positive. * Anti-MDA5 antibody positive DM patients with RPILD meet the diagnostic criteria for RPILD. * Must have undergone bronchoalveolar lavage. * Age≥18 years old. * Patients who signed informed consent forms Exclusion Criteria: * Patients who had other connective tissue diseases. * Patients with ILD or RPILD caused by infection, tumors, drugs, biochemistry and other factors. * Pregnant or lactating patients. * The patient also participated in any other clinical trial. * Disagreement for inclusion in this study
Study design
Enrollment target: 50 participants
Age groups: adult, older_adult
Timeline
Starts: 2024-01-20
Estimated completion: 2026-11-25
Last updated: 2024-01-12
Primary outcomes
  • • The relationship between the microbial community and the presence or absence of interstitial lung disease (6 months)
Sponsor
Chinese PLA General Hospital · other
Contacts & investigators
ContactZhimei Duan, doctor · contact · 549117002@qq.com · 13716376758
All locations (1)
PLARecruiting
Beijing, Beijing Municipality, China
Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease · TrialPath